⚡ StockFin Pro 100-stock AI Radar. No daily limits. No ads. View Plans →

Mankind Pharma Limited (MANKIND) — Board Meeting | 26 August 2026(2 announcements)

· NSE 🟡 Notable Neutral
By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings
1 Board Meeting 🟡 Notable Neutral 📄 PDF
📢 Key Event
Board approved voluntary liquidation of BSVL to consolidate operations
🔄 What Changed
Voluntary liquidation of BSVL approved
🔮 What's Next
Liquidation to be undertaken by appointed liquidator under IBC 2016 and SEBI regulations
💡 Investor Takeaway
This consolidation may improve margins but requires regulatory approvals that could delay execution.

Mankind Pharma announced the board approved voluntary liquidation of its 96% owned subsidiary Bharat Serums and Vaccines Limited (BSVL) to consolidate operations. BSVL's business will be transferred to Mankind Pharma upon regulatory approvals, with Appian receiving cash equivalent to 4% of BSVL's fair value. The restructuring aims to improve operational efficiency, resource utilization, and governance while eliminating duplicate compliance costs. No promoter benefits or shareholding changes are expected.

2 Board Meeting 🟡 Notable Neutral 📄 PDF
📢 Key Event
Board approved voluntary liquidation of BSVL and its consolidation into Mankind Pharma.
🔄 What Changed
Consolidation of BSVL business into parent company; Appian to receive cash payout; no shareholding change.
🔮 What's Next
Liquidation to be executed by appointed liquidator under IBC 2016 and SEBI regulations; distribution upon receipt of approvals and licenses.
💡 Investor Takeaway
This restructuring simplifies the corporate structure and may improve operational efficiency and cash management for Mankind Pharma.

Mankind Pharma announced that its board approved the voluntary liquidation of its 96%-owned subsidiary Bharat Serums and Vaccines Limited (BSVL), enabling consolidation of BSVL's business into the parent company. Appian, holding 4% of BSVL, will receive cash equivalent to 4% of BSVL's fair value upon distribution. The liquidation will be executed by an appointed liquidator under applicable insolvency laws, with no change to the Company's shareholding pattern. The move aims to enhance operational efficiency, resource utilization, and governance while reducing compliance burdens.

⚡ StockFin Pro 100-stock AI Radar. No daily limits. No ads. View Plans →
📊 Stock Analysis — MANKIND ✨ Ask AI About This

About Mankind Pharma Limited (MANKIND)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹97,467.05 Cr P/E: 47.7 ROE: 12.7% ROCE: 13.9% Div Yield: 0.04%

View full MANKIND stock details →

📡 Get AI alerts when MANKIND files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track MANKIND — Free

💡 Ask AI about this filing

Ask AI Free →

📊 More MANKIND filings

See all MANKIND filings →

🔥 Also filed on 26 August 2026

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when MANKIND files new disclosures

Track MANKIND filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track MANKIND — Free

Free account · 2 AI queries/day

⚡ StockFin Pro Go Pro — bigger Radar, no daily limits Upgrade

© 2026 StockFin.ai — AI-powered Indian stock research

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd